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Genetic risk for renal artery stenosis: Association with deletion poly-
morphism in angiotensin 1-converting enzyme gene. Atherosclerotic renal
artery disease is an important secondary cause of hypertension. Currently,
there is great interest in possible genetic determinants of cardiovascular
disease. The ACE-D allele has been reported to be associated with
increased risk of myocardial infarction as well as coronary re-stenosis after
angioplasty. We therefore assessed whether this allele is also linked to
renovascular disease by studying 56 Caucasian subjects with atheroscle-
rotic renal artery stenosis and 74 age, sex and race matched control
subjects. Genetic analysis for the ACE l/D polymorphism was performed
on peripheral leukocytes using PCR techniques, including insertion-
specific primers. The distribution of I and D alleles was: renal artery
stenosis 8 II, 25 ID, 23 DD; and controls, 16 II, 41 ID, 17 DD. The
frequency of the D allele in the renal artery stenosis group was signifi-
cantly higher (D/total 71/112 = 0.66) than that of the control population
[75/148 = 0.51; ,2 = 4.17, P = 0.04; odds ratio 1.69 (95% CI 1.02 to 2.78)].
Our results suggest that the ACE-D allele may be associated with
increased risk of vascular disease at sites other than the coronary
circulation.
Atheromatous renal artery stenosis is an important and poten-
tially reversible cause of secondary hypertension. Environmental
factors that make vascular disease more likely such as smoking
and hyperlipidaemia are strongly associated with its development
[1]. In addition, patients who have vascular disease at other sites
are at increased risk of atheromatous disease in the renal arteries
[2, 3]. However, the role of genetic predisposition in renal artery
disease has not been previously studied.
Recently, the ACE-D allele has been reported to be associated
with increased risk of arterial re-stenosis in patients who have
undergone coronary artery angioplasty [4, 5]. There has also been
great interest in recent reports that this deletion variant of the
gene expressing angiotensin-converting enzyme is linked to in-
creased incidence and severity of cardiovascular disease [6—8].
The risk conferred by the presence of the ACE-D allele is
particularly apparent in the subjects who seem to be at low
coronary risk from classical risk factors. However, the mechanism
underlying this association is not as yet clear. Angiotensin con-
verting enzyme circulates in plasma and is present on the surface
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of endothelial cells. This enzyme stimulates conversion of inactive
angiotensin Ito the highly active octapeptide, angiotensin II (Ang
II). Ang II is a potent vasoconstrictor and may also increase
growth of vascular smooth muscle cells, particularly after endo-
thelial injury [9—11]. Inhibitors of angiotensin converting enzyme
prevent myo-intimal proliferation after vascular injury [12]. ACE
also inactivates bradykinin, a vasodilator and inhibitor of vascular
smooth muscle cell proliferation, which can stimulate the release
of endothelial vasodilator factors, including nitric oxide and
prostacyclin [13, 14]. Levels of circulating ACE activity are under
tight genetic control and are significantly higher in subjects with
the above deletion polymorphism [15, 16]. The increased risk of
myocardial infarction associated with this ACE-D allele is graded
with low risk for the ACE-Il to intermediate risk for ACE-ID to
high risk for ACE-DD genotypes, suggesting co-dominant inher-
itance characteristics [6].
We therefore investigated whether the ACE-D allele is also
linked to atheromatous renovascular disease by studying patients
with angiographically confirmed atheromatous renal artery steno-
sis compared to control subjects matched for age, gender and
ethnic group.
Methods
We studied 56 Caucasian hypertensive subjects who were
consecutively diagnosed as having renal artery stenosis. They were
seen in the Blood Pressure Unit between August 1993 and May
1994. Clinical indications for performing renal digital subtraction
angiography [17] included the presence of: (1) severe hyperten-
sion requiring more than two drugs to control blood pressure; (2)
hypertension with renal dysfunction in the absence of intrinsic
renal disease; and (3) additional risk factors for atherosclerosis
such as smoking and hyperlipidemia.
The mean age (± 5EM) was 66.5 1.2 years (95% CI 64 to 69).
Thirty-three were male and 23 female. Supine systolic and dia-
stolic blood pressures were recorded three times, two minutes
apart, using a semiautomated ultrasound sphygmomanometer
(Arteriosonde, Roche) [18]. Non-fasting venous blood samples
were taken at the same time with the subjects seated and without
stasis for genetic analysis, determination of serum electrolytes,
creatinine, blood glucose and cholesterol. Subjects gave informed
consent for these studies, which were approved by the hospital
ethical committee.
Seventy-four control subjects with no clinical history of vascular
disease and matched for sex, age and race [mean age 63.8 1.5
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Table 1. Frequencies of ACE alleles and genotypes in patients with
renal artery stenosis and normal controls
Renal artery
stenosis
N(%)
Controls
N (%)
Alleles
I
71(63)
41(37) 73 (49)
75 (51)
= 4.17 (P = 0.04)
Genotypes
DD 23 (41) 17 (23)
ID 25 (45) 41(55)
II 8 (14) 16 (22)
= 5.05 (P = 0.08)
years (95% CI 60.8 to 66.8)] were also recruited from the local
population (1:1 in 38 subjects, and, for the remaining 18 subjects,
2 controls matched per renal artery stenosis patient were re-
cruited, in order to increase the power of the study).
DNA was extracted from 100 rl of whole blood for PCR
analysis, by addition 400 .tm of 0.17 M ammonium chloride. Tubes
were mixed for 20 minutes, put in a microcentrifuge for two
minutes, and the supernatant removed and discarded. Pellets
were washed with 0.85% saline, which was removed before the
addition of 200 j.tl of 0.5 M sodium hydroxide. Samples were boiled
for 10 minutes, then neutralized with 40 ml of 1 M Tris pH 7.5.
Samples were stored at —20°C until assay. The l/D ACE poly-
morphism, the presence or absence of an insertion in intron 16 of
the ACE gene, was detected using PCR techniques to amplify
DNA fragments and the reaction products analyzed on 1.5%
agarose gel electrophoresis as previously published [191. The I
allele corresponded to a 490 bp fragment in the presence of the
insertion and the D allele to a 190 bp fragment in the absence of
the insertion. Patients and controls were thus divided into three
genotypes, II, ID, DD depending on the result of the ACE
genotyping.
Five percent dimethyl sulphoxide (DMSO) was used in the
assay to avoid the possibility of false DD genotyping in ID
individuals [201. In view of recent concern about the risk of
mistyping ID as DD, despite the use of DMSO, the PCR studies
were also repeated using insertion-specific primers [21]. There
were no ACE mistypings in any of the patients or control subjects.
Circulating ACE activity was measured as previously described
[221. There is some confusion in the literature with regard to
sampling conditions for blood ACE measurements. We therefore
first compared the results for circulating angiotensin converting
enzyme activity in a separate group of 10 subjects (7 male, 8 white,
2 black, age 54 5 [range 29 to 79] years) in a blood sample taken
on a single visit for serum and for plasma obtained in two standard
ways: using lithium heparin or EDTA containing sample tubes.
There was close agreement between results for ACE activity in
serum (50 6 lU/liter) compared with lithium heparin plasma (52
6 lU/liter; Pearson r = 0.987, P < 0.001). However, in all
subjects ACE activity in EDTA plasma was low at  61U/1. We
therefore then measured circulating ACE activity in lithium-
heparin plasma in our patients with renal artery stenosis for whom
appropriate samples were available (N = 21).
Statistics
The data are expressed as means SEM, cross tabulation
statistics (with Yates' correction when necessary) were used to test
Table 2. Distribution of clinical characteristics and ACE I/D
polymorphism in patients with renal artery stenosis
ACE genotype
II ID DD
Number of patients N 8 25 23
Mean age years 65.9 2.9 68.8 1.4 64.2 2.4
Sex male.femaies 4:4 15:10 14:9
Supine BP mm Hg 167/86
11/5
176/92
4/3
184/95°
6/3
Mean cholesterol mmoi/liter 6.4 0.5 6.4 0.2 6.3 0.3
Plasma creatinine unoi/liter 163 35 142 14 188 23°
Smoking ratio of never:ex-:current
Renal artery stenosis uniiateral:biiaterai
0:6:2
6:2
7:11:7
17:8
5:12:6
12:11"
Ischemic heart disease N 4 5 1
Peripheral vascular disease N 3 9 7
Cerebrovascular disease N — 4 1
Results are means SEM.
aNo significant difference using analysis of variance
No significant difference on y comparison
for differences between frequency data. A P value of <0.05 was
considered statistically significant. Phenotypic values within dif-
ferent ACE-genotypes were assessed by one-way ANOVA within
each subject group.
Results
Genetic analysis
The frequency of the D allele in the renal artery stenosis group
was significantly higher (D/total: 71/112 = 0.66) than that of the
control population (75/148 = 0.51; = 4.17, P = 0.04) (Table 1).
The odds ratio for this difference was 1.69 (95% CI 1.02 to 2.78).
There was also a tendency for patients with renal artery stenosis to
have an increased frequency of the DD genotype when compared
to the controls (P = 0.08).
The distribution of the ACE genotypes in patients with renal
artery stenosis was as follows: 8 II, 25 ID, 23 DD. In the control
group the distribution of the ACE genotype was in Hardy-
Weinberg equilibrium (16 II, 41 ID, 17 DD).
Clinical data
The clinical and demographic data of patients with atheroscle-
rotic renal artery stenosis and the controls are shown in Tables 2
and 3, respectively. Digital subtraction angiography demonstrated
that 35 patients had unilateral renal artery stenosis (3 with <50%
and 25 with  50% disease; 7 with an occluded vessel) and 21
bilateral disease (11 with two vessel disease of  50% severity and
7 with one vessel occluded). Mean supine blood pressure of
patients with renal artery stenosis on entry into the study was
178/93 4/2 mm Hg, mean cholesterol 6.4 0.2 mmol/liter and
mean creatinine was 164 13 .rmol/1iter. All were on treatment
with at least one drug for high blood pressure. Of interest, patients
with the ACE-DD genotype had trends for higher blood pressure,
worse renal function and more severe atheromatous renal artery
stenosis, with a higher proportion having bilateral disease (Table 2).
The distribution of age, smoking history and cholesterol were
similar between the three types of ACE polymorphism. However,
in the renal artery stenosis group, a large number of subjects were
either ex- or current smokers when compared to the controls. In
the control group, supine blood pressure was 134/83 2/2 mm Hg
and cholesterol was 5.5 0.1 mmol/liter. None was on treatment
with a vasoactive or lipid lowering drug.
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Table 3. Distribution of clinical characteristics and ACE l/D
polymorphism in control group
ACE genotype
II ID DD
Number of subjects N 16 41 17
Mean age years 66.0 3.5 61.3 1.9 68.1 2.7
sex male.females 10:6 20:21 13:4
Supine BP mm Hg 137/83 132/83 134/86
Mean cholesterol mmol/liter 5.7 0.2 5.4 0.2 5.5 0.2
Smoking ratio never:ex-:current 13:3:0 36:5:0 11:5:1
Results are means SEM.
Circulating angiotensin converting enzyme activity
Blood samples were available for measurement of circulating
angiotensin converting enzyme activity in 21 of the patients with
renal artery stenosis. There was a trend for greater circulating
ACE activity in patients with the ACE-DD genotype (median
[interquartile range] for II - 33 [47] lU/liter, N = 3; ID - 36 [43]
lU/liter, N = 10; DD - 63 [44] IU/l, N = 8; for subjects with
ACE-DD compared with subjects with ACE-ID or -II: P = 0.135,
Mann-Whitney U-test).
Atherosclerosis affecting other vessels
Twenty-six patients with renal artery stenosis had no clinical
history or signs of atheroma affecting other vessels (1 II, 11 ID, 14
DD). In contrast, 30 patients had evidence of atheroma in other
vessels (Table 2).
Coronary artery disease. Ten patients had current or previous
features of ischemic heart disease (myocardial infarction 5 ID, 1
DD; angina 4 II).
Peripheral vascular disease. A total of 19 patients had angio-
graphic and/or clinical evidence of peripheral vascular disease or
an abdominal aortic aneurysm (3 II, 9 ID, 7 DD).
Carotid artery disease. Five patients had ultrasound evidence of
carotid artery disease or had suffered a cerebrovascular event
(stroke 1 ID, I DD; carotid disease 3 ID).
However, subjects were not systematically investigated for vascular
disease at other sites. It is likely that a higher proportion of subjects
with vascular disease would have been found if this had been done.
Discussion
Atheromatous disease of the renal arteries is an important
secondary cause of hypertension and is associated with a high
mortality from cardiac and cerebrovascular disease [2, 3]. Our
study shows that patients with atherosclerotic renal artery stenosis
have a significantly higher frequency of the ACE-D allele when
compared to matched control subjects. Our finding complements
several other case-control studies that have reported an associa-
tion between the ACE-D allele and a wide spectrum of cardio-
vascular and other diseases, including cardiac hypertrophy [23, 24]
and remodeling [25], ischemic or idiopathic dilated cardiomyop-
athy [26], hypertrophic cardiomyopathy [27], and diabetic ne-
phropathy [28]. However, not all studies have been positive [29,
301. For example, in a large case control study, Lindpaintner et al
[291 failed to find the expected association between ACE gene
alleles and myocardial infarction. One explanation may be type III
errors in smaller, previous positive studies. This seems unlikely,
although possible in view of bias against reporting and publishing
negative results. An alternative explanation is that the presumably
more heterogenous genetic background of Lindpaintner's North
American population compared to European studies resulted in
loss of linkage disequilibrium between the ACE- D-I markers and
another disease mutation, leading to the negative results [31].
However, several of the published positive studies have also been
conducted in North American populations (such as [8, 25, 26]).
Lindpaintner's study may have been confounded by bias in
selective use of ACE inhibitors and/or aspirin in DD patients in
the study group. Also, patients in the Lindpaintner study were
older than in some previous positive studies, and therefore
environmental factors may have been more likely to mask genetic
mechanisms such as that marked by presence of the ACE-D allele.
A further, recently recognized, methodological problem in
studies of ACE-D allele is false identification of DD genotype in
individuals who in fact have the ID genotype. We minimized the
risk of this by using DMSO in our assay [20] and by repeating the
PCR using insertion-specific primers [21].
There are several possible mechanisms for the increased risk of
renal artery disease associated with the presence of ACE-D allele.
These mechanisms could be linked to the expression of active
angiotensin-converting enzyme in plasma or on endothelial cells,
or could be due to products expressed by a gene or by several
genes in linkage disequilibrium with the ACE gene.
The ACE polymorphism is largely responsible for the between-
individual variation in circulating levels of ACE: subjects with a
DD phenotype have approximately twice the levels of ACE in
serum compared to II subjects [15]. Our results are consistent with
a role for increased circulating ACE expression as a possible
mechanism for ACE-DD associated atheromatous renal artery
disease. Angiotensin converting enzyme is responsible for the
metabolism of two important peptides which have opposing
effects on vascular tone and on proliferation of vascular smooth
muscle cells. Firstly, Ang II generated by ACE is associated with
vasoconstriction and with a number of mechanisms linked to
atherosclerosis, particularly in the presence of damaged endothe-
hum [9—11]. In contrast, bradykinin which is catabolized by ACE
can act as a vasodilator and can also inhibit vascular smooth
muscle cells directly as well as by its effects through release of
nitric oxide and prostacyclin [13, 14]. Thus, increased expression
of ACE could promote atherogenesis, by increased circulating
and/or local angiotensin II levels and by reduction in bradykinin
levels. Once intimal damage has occurred, the presence of the
ACE-D allele could, by these same mechanisms, contribute to
accelerated atherogenesis.
An alternative explanation is that the ACE-D allele may not be
involved directly in disease pathogenesis, but could be linked with
the product of another culprit gene. This hypothesis is supported
by the findings that Afro-Caribbeans and West Africans have a
higher frequency of the D allele than Caucasians [32, 33] despite
a low incidence of arterial disease. This could, however, equally be
explained by the importance of environmental factors (such as
smoking, hyperhipidemia), the absence of which could blunt the
observed increase in risk of atherosclerotic renal artery stenosis in
our study in Caucasian subjects.
An obvious difference between the renal artery stenosis patients
and the control subjects was a higher blood pressure in patients
with renovascular disease, as this was the main reason for referral
of these patients to our Unit. However, there is no evidence of any
association between the ACE-D allele and systemic blood pres-
sure [34, 35]. Furthermore, although renal angiograms were not
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performed in the control subjects for ethical reasons, the preva-
lence of renal artery disease is extremely low in normotensive
asymptomatic subjects [36, 37].
In conclusion, our results clearly suggest that, in addition to
being linked to vascular disease in the coronary arteries [6, 71, the
ACE-D allele is also a risk factor for atheromatous renal artery
stenosis. This finding could give new clues to underlying mecha-
nisms for atheromatous renal artery stenosis either directly me-
diated by increased levels of circulating or local ACE or indirectly
through the effects of neighboring genes.
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